L606 for Pulmonary Hypertension from Lung Disease
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
Recruiting
Phase 3
Interventional Study
Pulmonary Hypertension Due to Lung Disease (Disorder)
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Trial phase
- Phase 3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 344 (estimated)
- Sponsor
- Liquidia Technologies, Inc. · Industry
Who this trial is looking for
This trial is looking for adults with high blood pressure in the lungs caused by lung disease. Participants will take either L606 or a placebo for comparison while doctors monitor their health and side effects.
Are You a Good Fit for This Trial?
You may be able to join if
- I am between 18 and 80 years old.
- I have lung disease confirmed by a CT scan.
- I have high blood pressure in my lungs as shown by heart tests.
- I have a lung function ratio that meets the study's criteria.
- I can walk at least 150 meters in six minutes.
You may not be able to join if
- I have different types of pulmonary hypertension that are not included.
- I have significant left-sided heart disease.
- I have a history of uncontrolled atrial fibrillation.
- I have severe obstructive sleep apnea.
- I have had a worsening lung disease or active infection recently.
- I have started pulmonary rehabilitation.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3). One of the main ways the study will check this is by seeing if people can walk further in six minutes (called the "six-minute walk test"). Another important (secondary) goal is to see how long it ta…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Participant is between 18 years to 80 years old.
* Has a confirmed diagnosis of ILD based on High Resolution Computed Tomography (HRCT) chest imaging.
* Evidence of PH as demonstrated from Right Heart Catheterization (RHC) with the following hemodynamic parameters:
* Pulmonary…
Contacts